Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Colorcon
Harvard Business School
Dow
Mallinckrodt

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Litigation Details for Cephalon Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2009)

See Plans and Pricing

« Back to Dashboard

Cephalon Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2009)

Docket   Start Trial Date Filed 2009-12-11
Court District Court, D. Delaware Date Terminated 2012-05-03
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties CEPHALON FRANCE; CEPHALON INC.; MATRIX LABORATORIES INC.; MATRIX LABORATORIES LIMITED; MYLAN INC.; MYLAN PHARMACEUTICALS INC.
Patents 7,132,570; 7,297,346
Attorneys Barbara R. Rudolph; Cedric C. Y. Tan; Charles E. Lipsey; Elham F. Steiner; James L. Higgins; John C. Englander; John W. Shaw; Laura P. Masurovsky; Mark J. Feldstein; Mark T. Jansen; Mary W. Bourke; Richard S. Meyer; Thomas L. Irving
Firms Shaw Keller LLP; Womble Bond Dickinson (US) LLP; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Cephalon Inc. v. Mylan Pharmaceuticals Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Cephalon Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2009)

Date Filed Document No. Description Snippet Link To Document
2012-04-27 120 .S. Patent No. 7,132,570 (the “‘570 patent”). However, Cephalon acknowledges that the ‘570 patent merely…long- expired patent covering armodafinil, U.S. Patent No. 4,927,855 (“the ‘855 patent”). Cephalon alleges…in the ‘570 patent. The prior art ‘855 patent inherently anticipates the ‘570 patent at issue in…570 patent. A. Preparation I of the Prior Art ‘855 Patent Anticipates the ‘570 Patent …Preparation I of the Prior Art ‘855 Patent Anticipates the ‘570 Patent....................... 5 B. External link to document
2010-02-12 16 Certiflcation also asserted that U.S. Patent No. 7,297,346 B2 (“the ‘346 Patent”), entitled “Pharmaceutical Formulations… U.S, Patent No. 7,297,346 (“the ‘346 patent”) in the Orange Book in connection with NDA No. 02-1875 for… Reissue Patent No. RE37,516 (“the ‘516 patent”), U.S. Patent No. 7,132,570 (“the ‘570 patent”), and U.S…346 patent. Cephalon did not assert the fourth patent, U.S. Patent No. 4,927,855 (“the ‘855 patent”), …holder/patent owner; (2) neither the NDA holder nor the patent holder has filed a suit for patent D130229254644.1 External link to document
2010-03-08 18 U.S. Patent No. 7,297,346 (“the ’346 patent”) are among the patents listed in the Orange Book in connection…Reissued Patent No. RE37,516 (“the ’516 patent”), U.S. Patent No. 7,132,570 (“the ’570 patent”), and U.S… regarding each of the ’5 16 patent, the ’570 patent, and the ’346 patent, and that l\/lylan has sought… the expiration of the ’5 16 patent, the ’570 patent, and the ’346 patent, and that l\/lylan Was providing… infringement of the ’516 patent, the ’570 patent, and/or the ’346 patent, and further reasserts and External link to document
2010-03-29 19 Certification also asserted that U.S. Patent No. 7,297,346 B2 (“the ‘346 Patent”), entitled c‘Pharrnaceutical … U.S. Patent No. 7,297,346 (“the ‘346 patent”) in the Orange Book in connection with NDA No. 02-1875 for… Reissue Patent No. RE37,516 (“the ‘516 patent”), U.S. Patent No. 7,132,570 (“the ‘570 patent”), and U.S…346 patent. Cephalon did not assert the fourth patent, U.S. Patent No. 4,927,855 (“the ‘855 patent”), …holder/patent owner; (2) neither the NDA holder nor the patent holder has filed a suit for patent infringement External link to document
2010-04-22 23 U.S. Patent No. 7,297,346 (“the ’346 patent”) are among the patents listed in the Orange Book in connection…Reissued Patent No. RE37,516 (“the ’5 16 patent”), U.S. Patent No. 7,132,570 (“the ’570 patent”), and U.S…certification regarding each of the ’516 patent, the ’570 patent, and the ’346 patent, and that Mylan has sought approval… the expiration of the ’516 patent, the ’5 70 patent, and the ’346 patent, and that Mylan Was providing…-infringement of the ’5 16 patent, the ’5 70 patent, and/or the ’346 patent, and further reasserts and External link to document
2011-06-17 44 CLAIM CONSTRUCTION OPENING BRIEF for Patent No. 7,132,570 - CORRECTED [ to add Joint Appendix "JA"…December 2009 3 May 2012 1:09-cv-00954 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Mallinckrodt
McKinsey
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.